Clinical trials: Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
The study is a two-year prospective observational study of patients treated with teriflunomide. The investigators will recruit up to 75 patients at baseline, based on the estimate that approximately 20% of these patients (~ 15…
- Trial name
- NCT03561402
- Testing
- Teriflunomide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis, Relapsing-Remitting
An Examination of Cognitive Fatigue Using Functional Neuroimaging
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04885894
- Testing
- Zeposia
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Relapsing Remitting Multiple Sclerosis, Fatigue
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity
- Trial name
- PAMS (NCT04115930)
- Testing
- Physical Activity measurement:
- Where
- 4 sites in Finland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Relapsing-remitting Multiple Sclerosis
Mass Balance Study of MT-1303
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
- Trial name
- NCT02293967
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Relapsing Remitting Multiple Sclerosis
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
- Trial name
- NCT05181215
- Testing
- Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
This is a prospective, observational, single-blinded, longitudinal, 24-month OCT study of the evolution of axonal loss, as evidenced by loss of RNFLT and TMV, in RRMS patients treated with GA and in healthy controls.
- Trial name
- GAO (NCT02017808)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis, Relapsing-Remitting
Efficacy of Diet on Quality of Life in Multiple Sclerosis
The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care.
- Trial name
- EDQ (NCT05007483)
- Testing
- BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Terry L. Wahls
Multiple Sclerosis, Clinically Isolated Syndrome
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
This project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
- Trial name
- NCT05706220
- Testing
- Eye tracking, Microperimetry, Optical coherence tomography (OCT)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Multiple Sclerosis, Relapsing-Remitting
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 3-part study where Parts A, B (single-blind - investigator and subject blind) will enrol healthy volunteers and Part C (open-label) will enrol RRMS patients.
- Trial name
- NCT01808482
- Testing
- Part A: 100 mg/mL GSK2618960, Part B: Dose of GSK2618960 decided from Part A, Part C: Dose of GSK2618960 decided from Part A and B
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01424462
- Testing
- A, B, C
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis-Relapsing-Remitting
Speech in Noise Discrimination Skills in Multiple Sclerosis Patients.
The aim of this clinical trial was to determine the effect of multiple sclerosis on speech reception and discrimination in noise and to compare the effects on the medial olivocochlear reflex, which is thought to affect speech…
- Trial name
- NCT06381297
- Testing
- Hearing test, Speech in noise discrimination test, Montreal Cognitive Assessment Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Asuman Kucukoner
Multiple Sclerosis, Remitting Relapsing Multiple Sclerosis
Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis
Multiple sclerosis (MS) is the most frequently acquired demyelinating disease and the first cause of non-traumatic chronic disability in young adults.
- Trial name
- MODIF-MS (NCT06330077)
- Testing
- Ifenprodil
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
The primary objective of this study was to assess the bioequivalence of the test product (Bafiertam; BLS-11; monomethyl fumarate) 190 mg versus Tecfidera® (dimethyl fumarate) 240 mg based on the Cmax and Area Under the Curve…
- Trial name
- NCT04570670
- Testing
- monomethyl fumarate 190 mg, dimethyl fumarate 240 mg
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Relapsing Remitting Multiple Sclerosis (RRMS), Malnutrition or Risk of Malnutrition
The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
This prospective observational study aims to determine the prevalence of malnutrition in patients with relapsing-remitting multiple sclerosis and to evaluate its association with disability.
- Trial name
- NCT07497126
- Where
- Turkey (Türkiye)
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.
- Trial name
- ONSTIM (NCT06389968)
- Testing
- Light stimulation
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich